Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide + G-CHOP in CDLBCL-FL
NCT06151080Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Nov 2023
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Complete remission rate up to 28 months. Started Nov 2023; status: recruiting.
02
Drugs
lenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT06151080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06151080.